Ernexa Therapeutics Inc.
ERNA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.13 | 0.07 | -0.01 |
| FCF Yield | -12.94% | -14.24% | -14.44% | -0.87% |
| EV / EBITDA | -3.44 | -8.92 | -5.83 | -22.09 |
| Quality | ||||
| ROIC | -617.57% | -47.20% | -199.26% | -402.25% |
| Gross Margin | 83.51% | -247.06% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.36 | 0.94 | 0.85 | 0.19 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 20.67% | 3.98% | 10.02% | -190.44% |
| Safety | ||||
| Net Debt / EBITDA | 0.03 | -1.72 | 0.30 | 0.12 |
| Interest Coverage | -2.32 | -34.42 | -1,107.23 | -1,536.92 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,269.32 | 631.02 | 0.00 | 0.00 |